Skip to content
Open access · CC-BY via OpenAlex

Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration

Philip S.J. Weston, Teresa Poole, Natalie Sarah Ryan, Akshay Nair, Yuying Liang, Kirsty Macpherson, Ronald Druyeh, Ian B. Malone, R. Laila Ahsan, Hugh Pemberton, Jana Klímová, Simon Mead, Kaj Blennow, Martin N. Rossor, Jonathan M. Schott

Neurology · 2017 · ▲ 253 citations

Abstract

Objectives: To investigate whether serum neurofilament light (NfL) concentration is increased in familial Alzheimer disease (FAD), both pre and post symptom onset, and whether it is associated with markers of disease stage and severity. Methods: We recruited 48 individuals from families with PSEN1 or APP mutations to a cross-sectional study: 18 had symptomatic Alzheimer disease (AD) and 30 were asymptomatic but at 50% risk of carrying a mutation. Serum NfL was measured using an ultrasensitive immunoassay on the single molecule array (Simoa) platform. Cognitive testing and MRI were performed; 33 participants had serial MRI, allowing calculation of atrophy rates. Genetic testing established mutation status. A generalized least squares regression model was used to compare serum NfL among symptomatic mutation carriers, presymptomatic carriers, and noncarriers, adjusting for age and sex. Spearman coefficients assessed associations between serum NfL and (1) estimated years to/from symptom onset (EYO), (2) cognitive measures, and (3) MRI measures of atrophy. Results: Nineteen of the asymptomatic participants were mutation carriers (mean EYO −9.6); 11 were noncarriers. Compared with noncarriers, serum NfL concentration was higher in both symptomatic (p < 0.0001) and presymptomatic mutation carriers (p = 0.007). Across all mutation carriers, serum NfL correlated with EYO (ρ = 0.81, p < 0.0001) and multiple cognitive and imaging measures, including Mini-Mental State Examination (ρ = −0.62, p = 0.0001), Clinical Dementia Rating Scale sum of boxes (ρ = 0.79, p < 0.0001), baseline brain volume (ρ = −0.62, p = 0.0002), and whole-brain atrophy rate (ρ = 0.53, p = 0.01). Conclusions: Serum NfL concentration is increased in FAD prior to symptom onset and correlates with measures of disease stage and severity. Serum NfL may thus be a feasible biomarker of early AD-related neurodegeneration.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1212/wnl.0000000000004667
Canonical
link ↗
Fetched
2026-11-13 MST

Cite this

APA
Weston, P.S., Poole, T., Ryan, N.S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I.B., Ahsan, R.L., Pemberton, H., Klímová, J., Mead, S., Blennow, K., Rossor, M.N., Schott, J.M., Zetterberg, H., &amp; Fox, N.C. (2017). Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. <em>Neurology</em>. https://doi.org/10.1212/wnl.0000000000004667
Vancouver
Weston PS, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration. Neurology. 2017. doi:10.1212/wnl.0000000000004667.
BibTeX
@article{philip2017Serumn, title = {Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration}, author = {Philip S.J. Weston and Teresa Poole and Natalie Sarah Ryan and Akshay Nair and Yuying Liang and Kirsty Macpherson and Ronald Druyeh and Ian B. Malone and R. Laila Ahsan and Hugh Pemberton and Jana Klímová and Simon Mead and Kaj Blennow and Martin N. Rossor and Jonathan M. Schott and Henrik Zetterberg and Nick C. Fox}, journal = {Neurology}, year = {2017}, doi = {10.1212/wnl.0000000000004667}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings